Based on the results of carefully designed experiments upgraded with appropriate theoretical modeling, we present clear evidence that the release curves from mesoporous materials are significantly affected by drug-matrix interactions. In experimental curves, these interactions are manifested as a non-convergence at long times and an inverse dependence of release kinetics on pore size. Neither of these phenomena is expected in non-interacting systems.
COBISS.SI-ID: 4727578
The aim of our study was to explain the observed influence of UGT1A1*28 genetic polymorphism on raloxifene pharmacokinetics where a significantly higher total raloxifene plasma concentration has been observed in patients homoygous for the polymorphic allele (*28/*28). Our in vitro metabolic study with genotyped human liver microsomes showed a significantly lower raloxifene intrinsic clearance in polymorphic homozygotes (*28/*28) compared to the wild-type homozygotes (*1/*1) which explains the observed effect in vivo.
COBISS.SI-ID: 3091313
We developed three novel lipidic formulations of erytromycin, prepared as medicated feeds and evaluated the effect on bioavailability after oral administration in rainbow trout. Pharmacokinetic model was used to predict the plasma concentration profiles with multiple dosing. We demonstrated that the feeds containing microemulsified erythromycin provided largely superior bioavailability.
COBISS.SI-ID: 2975089